Bioptimus’ H-optimus-0 Model Now Integrated with Proscia’s Concentriq® for Fast AI Development
Bioptimus, a leading French AI startup, has announced the integration of its H-optimus-0 foundation model into Proscia’s Concentriq® Embeddings platform. With 1.1 billion parameters, H-optimus-0 is the largest open-source AI model designed specifically for pathology, offering state-of-the-art performance in critical tasks like detecting cancerous cells and identifying genetic abnormalities in tumors. This integration will accelerate AI-driven research, drug development, and diagnostics.
Through Concentriq Embeddings, AI developers and research scientists can apply their organization’s proprietary datasets to H-optimus-0, seamlessly incorporating the model into routine R&D workflows. The Concentriq platform stores, enriches, and analyzes data from discovery to clinical trials, making it an ideal environment for leveraging the power of H-optimus-0.
David Cahané, Co-Founder and General Manager at Bioptimus, said: “H-optimus-0 has set new benchmarks in AI performance. By integrating it into Concentriq Embeddings, Proscia’s users now have access to a tool that accelerates model development and drives breakthroughs in precision medicine and therapeutic research.”
H-optimus-0 has been trained on over 500,000 pathology slides, making it capable of generalizing across diverse cases and consistently outperforming existing models. Its integration with Proscia’s real-world data (RWD) enhances its scalability, allowing it to impact multiple therapeutic areas and bringing AI-driven innovations to pathology faster.
David West, CEO at Proscia, added: “With H-optimus-0, our users can rapidly build high-performing algorithms at scale, helping advance precision therapies and diagnostics.”
Bioptimus will join Proscia’s upcoming webinar to discuss how foundation models like H-optimus-0 are transforming AI development in pathology and accelerating precision medicine breakthroughs.
About Bioptimus
Bioptimus is building the reference AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies and accessing unique proprietary data at scale, we aim to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. For more information, please visit https://www.bioptimus.com.
About Proscia
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer. 14 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia’s solutions each day. The company has FDA 510(k) clearance and was the first to secure CE-IVDR certification to advance digital pathology primary diagnosis in the European Union.
